KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deferred Tax Liability (2016 - 2025)

Astrazeneca (AZN) has 3 years of Non-Current Deferred Tax Liability data on record, last reported at $3.5 billion in Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability rose 5.9% year-over-year to $3.5 billion; the TTM value through Dec 2025 reached $3.5 billion, up 5.9%, while the annual FY2025 figure was $3.5 billion, 5.9% up from the prior year.
  • Non-Current Deferred Tax Liability reached $3.5 billion in Q4 2025 per AZN's latest filing, up from $3.3 billion in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $3.5 billion in Q4 2025 and bottomed at $2.8 billion in Q4 2023.
  • Average Non-Current Deferred Tax Liability over 3 years is $3.2 billion, with a median of $3.3 billion recorded in 2024.
  • Peak YoY movement for Non-Current Deferred Tax Liability: grew 16.21% in 2024, then rose 5.9% in 2025.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $2.8 billion in 2023, then increased by 16.21% to $3.3 billion in 2024, then increased by 5.9% to $3.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $3.5 billion in Q4 2025, $3.3 billion in Q4 2024, and $2.8 billion in Q4 2023.